Furthermore, HFpEF therapies targeting cardiac energetics and metabolism such as semaglutide (glucagon-like peptide-1, GLP-1, agonist) and Dapagliflozin (Sodium glucose transport protein 2 inhibitor—SGLT2i) have been shown to reduce worsening HF [62,63]. This evidence concerns the gene GCG and hydrops fetalis.